EP3341029A1 - Production method of iodophor based antimicrobial hydrogel - Google Patents
Production method of iodophor based antimicrobial hydrogelInfo
- Publication number
- EP3341029A1 EP3341029A1 EP16729403.2A EP16729403A EP3341029A1 EP 3341029 A1 EP3341029 A1 EP 3341029A1 EP 16729403 A EP16729403 A EP 16729403A EP 3341029 A1 EP3341029 A1 EP 3341029A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pvp
- iodine
- production method
- hydrogel
- based antimicrobial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 69
- 239000000017 hydrogel Substances 0.000 title claims abstract description 43
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 35
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 86
- 239000011630 iodine Substances 0.000 claims abstract description 82
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims abstract description 23
- 239000002253 acid Substances 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 13
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 10
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims abstract description 8
- 239000001230 potassium iodate Substances 0.000 claims abstract description 4
- 229940093930 potassium iodate Drugs 0.000 claims abstract description 4
- 235000006666 potassium iodate Nutrition 0.000 claims abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 90
- 238000000034 method Methods 0.000 claims description 42
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 14
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 12
- 235000019441 ethanol Nutrition 0.000 claims description 9
- 206010052428 Wound Diseases 0.000 claims description 8
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 7
- 239000000645 desinfectant Substances 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 38
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 239000007864 aqueous solution Substances 0.000 abstract description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 87
- 239000000523 sample Substances 0.000 description 17
- 229940064804 betadine Drugs 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 229940035535 iodophors Drugs 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000010419 agar Nutrition 0.000 description 4
- 239000003899 bactericide agent Substances 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000174 gluconic acid Substances 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 3
- 150000002496 iodine Chemical class 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000607447 Yersinia enterocolitica Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- WRTMQOHKMFDUKX-UHFFFAOYSA-N triiodide Chemical compound I[I-]I WRTMQOHKMFDUKX-UHFFFAOYSA-N 0.000 description 2
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910000881 Cu alloy Inorganic materials 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010067997 Iodine deficiency Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 229910000990 Ni alloy Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000004694 iodide salts Chemical group 0.000 description 1
- 235000006479 iodine deficiency Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940076266 morganella morganii Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- FJWLWIRHZOHPIY-UHFFFAOYSA-N potassium;hydroiodide Chemical compound [K].I FJWLWIRHZOHPIY-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/12—Iodine, e.g. iodophors; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
Definitions
- This invention is related to production method of a hydrogel in which antimicrobial effect is enhanced thanks to formation of polyvnylprolydone-iodine (PVP-I) containing nascent iodine in spite of reduced polyvnylprolydone (PVP) ratio as compared to its equivalents containing PVP-I.
- PVP-I polyvnylprolydone-iodine
- PVP polyvnylprolydone-iodine
- iodine was a valuable medicament and superior antimicrobial with its extraordinary effective range. Human body needs this element and iodine deficiency results in goiter disease. Since a long time, iodine solutions are used as wide-spectrum bactericide agents having effect on a wide range of microorganisms such as gram positive and negative bacteria, yeast, viruses and fungi. Iodine forms in certain oxidation situations including wholly degraded iodide ( ⁇ ), oxidation diatomic free element (I 2 ), and certain high oxidation conditions combined with oxygen (for example hypo-iodate (10 ), iodate (IO 3 ) and periodate (I0 4 ⁇ )).
- ⁇ wholly degraded iodide
- I 2 oxidation diatomic free element
- I0 4 ⁇ certain high oxidation conditions combined with oxygen
- iodide forms the efficiently dissolving tri-iodide (I 3 ) balance complex in the form of elemental iodine and in bonded iodine form with no antimicrobial activity.
- I 3 tri-iodide
- iodine It is difficult to process iodine in its free form as it enters into chemical reaction with certain substances in and out of the body. It is also volatile and it sublimates in the atmosphere. Iodine dissolves in pure water only slightly and but if water contains iodide or iodine salt composed of poly-iodine and iodine, iodine will dissolve easier. Iodine must be in dissolved state in order that it can be used for forming useable solutions. There are many dissolution approaches and some of them are given below. First of all, Lugol's solution made in 1829 was a water based solution containing 1-5% iodine and 5-10% potassium iodine.
- Alcoholic solution of elemental iodine in the form of iodine tincture containing 2-7% molecular iodine was accepted as the most effective bactericide combination for a very long time.
- Lugol's solution and iodine tincture fell out of favor in the recent years due to the fact that they tend to cause chemical burns and tissue colorations and because of their relative instabilities, short term effects and characteristic odors. These solutions may cause swelling and bleeding of mucous membrane and they will be highly toxic when they contact with the bruises on the body.
- one 1% iodine tincture solution might release extra 10000 ppm iodine powder. For that reason diluted concentrations are recommended.
- Iodophors are known as products forming through complex formation of iodine with polymers.
- Complex agents used for that purpose are polyvnylprolydone (povidone or PVP), polyvinyl alcohol, polyurethane, cadexomers (recycled carbohydrate polymer complexes mixed with elemental iodine formulated in polyethylene glycol) and polydextrase (non-digestible polysaccarite.
- PVP-I polyvnylprolydone
- PVA-I polyvinyl alcohol
- polyurethane polyurethane
- cadexomers cycled carbohydrate polymer complexes mixed with elemental iodine formulated in polyethylene glycol
- polydextrase non-digestible polysaccarite.
- Iodophors are free complexes of elemental iodine and tri-iodide. They process iodine to add a continuous oscillation to iodine and serve as a polymeric carrier increasing solubility of iodine.
- neutral and water soluble principal commercial polymers containing PVP were used as carrier.
- PVP is an organic polymer characterized with its colloidal features and physical immobility and it is devoid of natural antimicrobial activity, exhibits high molecular change, and it is non- ionic, non-detergent, water soluble, with extraordinary complex ability. Carriers may also exhibit variable degrees of effect increasing surface activity or dampen the solution in which they are used.
- iodophor complexes are in the form of groped mycelium which is dispersed by water or bodily fluids. Until the iodine gets free to form antimicrobial concentrations, the bonding of iodine with polymer gradually weakens.
- Betadine is available in Swiss market. Contrary to iso-Betadine, Braunol and Betadine are stabilized with NaI0 3. For that reason, hereinafter Betadine will be referred to as standardized Betadine. And on the contrary, iso-Betadine will be referred to as non- standardized iso-Betadine. Lugol's solution contains 170 mg/L free iodine and non- standardized iso-Betadine is concentrated 85,17 and 8,5 times more then standardized Betadine and Braunol respectively.
- these iodine complexes in aqueous solution is less concentrated and can mix better with bodily fluids and disperse relatively faster and as they highly reduce tissue irritation, bad odor, tissue coloring and corrosion on metal surfaces of medical materials, they are preferred to Lugol's solution and iodine tincture.
- Braunol contains 7,5% PVP and 0.75% iodine
- Betadine and iso-Betadine contains approximately 90% water, 8,5-9% PVP and 1% iodine. Since it I not possible with the available production methods to dissolve more elementary iodine iside PVP, PVP/iodine ratio in all of these products remained fixed as 1/10. Severe toxicological restrictions caused by PVP-I complexes when they are used widely on the body can be attributed to high iodine content in their combination since they are absorbed by the body and result in concentrations in the thyroid glands.
- Quantities of iodine and PVP in iodine containing commercial bactericides are a necessary parameter to ensure legal compliance and effect and acceptance by the consumers.
- Primary element in the cost of iodine containing commercial bactericides is costs of iodine and PVP. Since iodine based antiseptics are special chemicals, the cost is critical in terms of product acceptability.
- Nascent iodine production has been investigated in order to resolve the problems inherent in PVP-I complexes.
- the patent document published in 2009 describes a method in which some current was applied between two electrodes placed in a glass container put into an electrolyte bath by using a certain amount of iodine. This effect allowing iodine atom to receive stimulation energy from the magnetic area caused a diatomic bond destroying the iodine molecules.
- the simplest method to produce iodine by nascent reaction is to prepare iodine tincture.
- iodine solution in weight inside ethyl alcohol is immersed in an electrolyte bath composed of copper sulfate, sulfuric acid and zinc chips and copper and nickel alloy anode on which AC current is connected is placed at both surfaces of the glass container.
- an electrolyte bath composed of copper sulfate, sulfuric acid and zinc chips and copper and nickel alloy anode on which AC current is connected is placed at both surfaces of the glass container.
- nano-iodine synthesis was investigated by using chemical design in back-bone structure that can dissolve in nature and allows production of minimum two populations of nano-iodine containing chemical compounds.
- First population of the particles might contain one pH buffer, additional compounds containing iodate (IO 3- " ) and iodide ( ⁇ ).
- Second population of particles might contain those components that would create a micro-frame in the range of 5 ⁇ pH ⁇ 6 which surrounds the first population of particles immediately.
- a and B particles populations are maintained in dry condition. Particles are dispersed evenly and they do not contact with each other in dry state. In tile antimicrobial medium is achieved while I 2 is created.
- This dressing product could be applied only to single or double layered stupe and it activated when it start to touch wound fluid. For that reason, this process may be applied only on antibacterial stupe and cannot be produced in liquid or gel form which restricts its application.
- Purpose of the invention is to find a production method for iodophor based antimicrobial hydrogel where polyvinylprolydone (povidone) and iodine complex in nascent and/or nano form.
- polyvinylprolydone povidone
- iodine complex in nascent and/or nano form.
- Another purpose of the invention is to find a production method for an iodophor based antimicrobial hydrogel that reduces skin irritation thanks to its lower iodine and PVP content as compared to the traditional antimicrobial iodophors.
- Another purpose of the invention is to find a production method for an iodophor based antimicrobial hydrogel that exhibits better and longer antimicrobial effect as compared to the traditional PVP-I complexes thanks to the use of iodine in nascent form in spite of its low PVP and iodine content.
- Another purpose of the invention is to find a production method for an iodophor based antimicrobial hydrogel that that could be used also as a solution with the addition of alcohol in it.
- Figure- 1 Flow chart of the invented method
- Figure-2 The table indicating the ratio of the components of the samples prepared by the invented method.
- Figure-3 The table comparing antibacterial efficiencies of the main samples prepared by the invented method and control samples.
- PVP polyvinylpyrrolidone
- the acid solution prepared in this manner is added preferably drop by drop into the PVP and iodine containing mixture and is mixed at the same time (104). Mixing process is done by using magnetic mixer and mixing process is continued until viscosity of the solution increases to such level that it would be difficult to mix it. Reactions occurring one after the other in this step are as follows.
- hydrogel composed of PVP and nascent iodine complex (PVP-I) is obtained (105).
- Optimum components of the antimicrobial hydrogel produced by the invented production method (100) will be 1,2% iodine and 4.4% PVP.
- Low pH medium, i.e. abundance of H + ions in the medium has great importance for continuous movement of A reaction toward right. For that reason, preferred pH is between 4 and 6. If pH gets higher in the medium, H + ions are consumed faster and as a result, the reaction is slowed down.
- acid quantity in step 104 might be used in excess up to 40% of stoichiometric need.
- Acid quantity must be kept optimum because making the medium more acidic would not greatly enhance antimicrobial activity of the end product and besides, excessively acidic medium would cause skin irritation.
- a and B reactions stay in balance during the production phase and during the shelf life of the product produced by the invented method (100).
- quantity of KI0 3 used in step 101 must exceed stoichiometric need by minimum 10% and PVP quantity must be as low as possible so that it could cover all surface of iodine that will be released during the reaction. In this manner, the compound can be produced economically and retains its consistency as viscous gel.
- ratios of stoichiometric component required so that antimicrobial hydrogel prepared by the invented method (100) would contain 1.2% nascent iodine would be 0.33% KIO 3 , 1,3% KI and 1,8% acid in weight.
- maximum 2.5% citric acid and 0,36% KIO 3 in weight are used in order to ensure continuity of A and B reactions.
- Hydrogel product obtained by the invented method (100) could be diluted by alcohol in 1: 1 ratio and used as a solution containing 2.2% PVP and 0.6% iodine. The tests run showed that even if the invented hydrogel is diluted with alcohol and used as a solution, it would exhibit better and longer antimicrobial activity as compared to the equivalent products.
- the same procedure is started dissolving citric acid by water and later added PVP to this solution. Finally, the solution contains 0,36 g of KIO 3 , 1,3 g of KI and 10 g of water added to the PVP, citric acid mixture. Mixing is continued by magnetic mixer until the increasing of viscosity of hydrogel has stopped.
- control samples were also compared with another group of samples prepared by molecular iodine and PVP dissolved in water in ratios given in Figure 4 (Al and A7) in terms of antimicrobial activity.
- Al and A7 the results of this comparison are given on a table in Figure 5.
- Agar diffusion method was used to determine antimicrobial activities.
- Each bacterium was infused to nutrient liquid media and yeast was infused to malt extract media and then they were diluted to contain 10 6 -10 7 kob/ml (unit producing colony per millimeter) microorganisms.
- Each bacterium was infused 250 ml into the medium in Erlenmeyer with a temperature of 43-45°C which contained 25 ml of sterile medium (for bacteria, Mueller Hinton agar and for yeast, malt extract agar).
- Agars that were infused with microorganism culture were poured into Petri dishes of 9 cm and after solidification, they were waited for 1 hour in 4°C.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR201505114 | 2015-04-27 | ||
| PCT/TR2016/050127 WO2016175727A1 (en) | 2015-04-27 | 2016-04-27 | Production method of iodophor based antimicrobial hydrogel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3341029A1 true EP3341029A1 (en) | 2018-07-04 |
Family
ID=56133018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP16729403.2A Withdrawn EP3341029A1 (en) | 2015-04-27 | 2016-04-27 | Production method of iodophor based antimicrobial hydrogel |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3341029A1 (en) |
| WO (1) | WO2016175727A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110037940A (en) * | 2019-05-22 | 2019-07-23 | 浙江欧洁科技股份有限公司 | A kind of sterilizing oral disinfection mouthwash and preparation method thereof and application method |
| CA3173273A1 (en) * | 2020-02-26 | 2021-09-02 | Carefusion Corporation | Systems and methods for sterilizing iodophor compositions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4113857A (en) * | 1977-05-16 | 1978-09-12 | The Purdue Frederick Company | Process for the preparation of iodophor compounds and methods for stabilizing iodophor pharmaceutical compositions containing the same |
| US6939569B1 (en) * | 1998-06-19 | 2005-09-06 | Oxibio, Inc. | Medical device having anti-infective and contraceptive properties |
| US6838050B1 (en) * | 1999-06-04 | 2005-01-04 | Oxibio, Inc. | Methods and devices for providing anti-infective activity to a medical device |
-
2016
- 2016-04-27 EP EP16729403.2A patent/EP3341029A1/en not_active Withdrawn
- 2016-04-27 WO PCT/TR2016/050127 patent/WO2016175727A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016175727A1 (en) | 2016-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Glucose-responsive biomimetic nanoreactor in bacterial cellulose hydrogel for antibacterial and hemostatic therapies | |
| Selvaggi et al. | The role of iodine in antisepsis and wound management: a reappraisal | |
| US3065139A (en) | Anti-infectant topical preparations | |
| US3930000A (en) | Silver-zinc allantoinate compositions and method of killing bacteria and fungi therewith | |
| CN111296476A (en) | Long-acting disinfectant containing potassium hydrogen persulfate and preparation method thereof | |
| US12317898B2 (en) | Antibacterial surface of metal-organic framework-chitosan composite films | |
| AU2014362252B2 (en) | Acid-solubilized copper-ammonium complexes and copper-zinc-ammonium complexes, compositions, preparations, methods, and uses | |
| WO2003080231A1 (en) | Colloidal nanosilver solution and method for making the same | |
| EP2874671A1 (en) | Anti-microbial gel formulations containing a silver (i) periodate | |
| FR2781645A1 (en) | BACTERICIDE CONTAINING IRON IONS | |
| CN104206413B (en) | A kind of thimerosal for haemodialysis control unit cleaning and sterilizing and preparation method thereof | |
| EP1183058B1 (en) | Anti-infective medical device and production method | |
| KR20080028419A (en) | Antibacterial substance | |
| WO2016175727A1 (en) | Production method of iodophor based antimicrobial hydrogel | |
| CN101785477A (en) | Polyoxyethylene nonyl phenyl ether iodine complex disinfecting solution and preparation method thereof | |
| CN107744524B (en) | Iodine-containing tincture antibacterial gel and preparation method thereof | |
| US5409697A (en) | Biocidal composition | |
| CN118340172B (en) | Active chlorine dioxide disinfectant and preparation method thereof | |
| CA2542634A1 (en) | Disinfecting teat care compositions | |
| Benk et al. | Economical method for producing nascent iodine products with aprotic solvents (NMP, DMSO) possessing highly effective antimicrobial properties | |
| CN112120040A (en) | Hypochlorous acid disinfectant and preparation method thereof | |
| CN103110572B (en) | Gynecological antimicrobial gel recipe and preparation method thereof | |
| GB2517107A (en) | Disinfectant containing a complex of iodine and cyclodextrin | |
| EP3389381B1 (en) | Production method for a pdms-i based antimicrobial solution | |
| CN110367276A (en) | A kind of sterilised liq and preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20180315 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BENK, AYSE Owner name: COBAN, ABDULLAH |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BENK, AYSE Inventor name: COBAN, ABDULLAH |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20190805 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20200214 |